Skip to main content
Caplight Logo









Alectos Therapeutics

Alectos Therapeutics

Private
BurnabyHealthcare & Life Scienceshttps://alectos.com/

Last Round

Strategic

Jun 6, 2022

Total Funding Raised

$15M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Alectos Therapeutics is a biotechnology company that discovers and develops novel small-molecule therapeutics for neurodegenerative and acute neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule therapeuticsdrug discoveryneurodegenerative diseasebiotechglycomicspreclinical developmentenzyme inhibitorsdrug licensingbiopharmalysosomal dysfunctionOGA inhibitorsGBA2 inhibitorsneuroprotective therapymedicinal chemistrypharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alectos Therapeutics Comparables

Compare Alectos Therapeutics with similar companies based on industry and business-model similarity.

Alectos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asceneuron
87%
Gain Therapeutics Inc
77%
Vanqua Bio
76%

Alectos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 6, 2022
StrategicAug 11, 2010

Key People

Founding team and executive leadership

Ernest McEachern

President & CEO

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 770% MoM to 2.4K.

  • Jul 21, 2025

    Grew 23% QoQ, from 13 to 16 employees.

Alectos Therapeutics Filings

Explore SEC and related filing metadata, where available.

Alectos Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Alectos Therapeutics's valuation, stock price, and market status.

Is Alectos Therapeutics a public or private company?

Alectos Therapeutics is a private company.

What is the current stock price of Alectos Therapeutics?

Alectos Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Alectos Therapeutics worth (valuation)?

Valuation information for Alectos Therapeutics is not publicly available.

Can I buy Alectos Therapeutics stock?

Alectos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Alectos Therapeutics's last funding round?

Alectos Therapeutics's most recent funding round was Strategic on June 6, 2022.

Who are the main investors in Alectos Therapeutics?

Investor information for Alectos Therapeutics is not publicly disclosed.

Will Alectos Therapeutics IPO soon?

No public IPO plans have been announced for Alectos Therapeutics.

How can I track Alectos Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alectos Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBurnaby
Employee Range11
Year Founded2007
Last FundingJun 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?